MET exon 14 and MET-amplified non-small-cell lung cancer: lines of therapy
3 standard-of-care settings across 2 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| MET | Advanced MET exon 14, first line or later | Capmatinib (GEOMETRY mono-1) or tepotinib (VISION); platinum-pemetrexed with or without pembrolizumab if the inhibitor is not tolerated or after it. | NCCN Guidelines: Non-Small Cell Lung Cancer | 86 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| EGFR | MET amplification after osimertinib in EGFR-mutated disease | Osimertinib plus savolitinib (SAVANNAH, SACHI) where available; amivantamab plus chemotherapy; platinum-pemetrexed. | OsimertinibSavolitinibOsimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior OsimertinibAmivantamabA Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib FailureMET amplification (bypass resistance) | NCCN Guidelines: Non-Small Cell Lung Cancer | 87 |
| MET | c-Met overexpression, previously treated non-squamous | Telisotuzumab vedotin (LUMINOSITY) after platinum chemotherapy; TeliMET NSCLC-01 versus docetaxel is confirmatory. | NCCN Guidelines: Non-Small Cell Lung Cancer | 86 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.